NCT02591264

Brief Summary

The aim of this study is to determine the role of human neutrophil peptide-1 to 3 in the occurrence of periprocedural myocardial infarction.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2015

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 28, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 29, 2015

Completed
3 days until next milestone

Study Start

First participant enrolled

November 1, 2015

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2016

Completed
Last Updated

October 29, 2015

Status Verified

October 1, 2015

Enrollment Period

1 year

First QC Date

October 28, 2015

Last Update Submit

October 28, 2015

Conditions

Coronary Thrombosis

Outcome Measures

Primary Outcomes (1)

  • Human Neutrophil Peptide Level

    Laboratory analysis and measurement of Human Neutrophil Peptide-1 to 3 levels

    Two hours

Interventions

Blood sampleOTHER

Blood sample drawn from participants for analysis of neutrophil peptide level

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Troponin negative patients assigned for stent implantation in our medical institution.

You may qualify if:

  • Troponin negative patients
  • Stable angina
  • Unstable angina
  • Positive screening tests

You may not qualify if:

  • Troponin positive
  • Technical failure of procedure
  • Hemodynamic unstability

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hillel Yaffe Medical Center

Hadera, 38100, Israel

Location

MeSH Terms

Conditions

Coronary Thrombosis

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesThrombosisEmbolism and ThrombosisVascular Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Central Study Contacts

Rami Abu Fanne, MD, PhD

CONTACT

972-50-3573694ramia@hadassah.org.il

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 28, 2015

First Posted

October 29, 2015

Study Start

November 1, 2015

Primary Completion

November 1, 2016

Study Completion

November 1, 2016

Last Updated

October 29, 2015

Record last verified: 2015-10

Locations

IL(1)